5 Must-Buy Penny Stocks to Invest In Now

2. Nuvation Bio Inc (NYSE:NUVB)

Number of Hedge Fund Holders: 40

Upside Potential: 159.25%

Stock Price: $4.90

Nuvation Bio Inc (NYSE:NUVB) is among the must-buy penny stocks to invest in now. RBC Capital analysts see bright prospects for Nuvation Bio Inc (NYSE:NUVB) in the glioma treatment market, which they say is underserved. On April 6, RBC Capital boosted its price target on Nuvation Bio stock to $20 from $13 and reiterated its Overweight rating.

For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital pointed out that there’s an unmet need in the glioma market, particularly in the high-grade glioma segment.

According to the firm, Nuvation Bio’s safusidenib could become a first-in-class treatment for high-grade glioma. The firm also sees potential for this drug candidate in the low-grade glioma market as well. In RBC Capital’s estimates, safusidenib could generate as much as $3.4 billion in US sales for Nuvation Bio.

Nuvation Bio’s safusidenib is in Phase 3 study. On February 9, Nuvation Bio provided protocol updates regarding the Phase 3 SIGMA trial of Nuvation Bio. The updates included expanding the trial following discussions with regulatory agencies, doctors, and advocacy groups, the company said.

Nuvation Bio added that the protocol updates reflected alignment with US regulators, mentioning potential for swift approval of safusidenib for patients who badly need a treatment option.

In Q4 2025, Nuvation Bio generated revenue of $$41.9 million, surpassing the consensus estimate of $38.55 million. It wrapped up the quarter with $529.2 million in cash, cash equivalents, and marketable securities.

Nuvation Bio Inc (NYSE:NUVB) is an American biopharmaceutical company founded in 2018. The company is focused on developing cancer medicines. It’s focused on tackling the toughest treatment cancer challenges.